Cart
sales@molnova.com
KD025
CAS No. 911417-87-3
KD025( SLx-2119 | SLx2119 | SLx 2119 | KD 025 )
Catalog No. M19254 CAS No. 911417-87-3
KD025 is an orally available, and specific ROCK2 inhibitor (IC50/Ki: 60/41 nM).
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 1 mL x 10 mM in DMSO | 68 | In Stock |
|
| 2MG | 39 | In Stock |
|
| 5MG | 64 | In Stock |
|
| 10MG | 87 | In Stock |
|
| 25MG | 161 | In Stock |
|
| 50MG | 245 | In Stock |
|
| 100MG | 368 | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | 877 | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameKD025
-
NoteResearch use only, not for human use.
-
Brief DescriptionKD025 is an orally available, and specific ROCK2 inhibitor (IC50/Ki: 60/41 nM).
-
DescriptionSLx-2119, also known as KD-025, is an orally bioavailable inhibitor of ROCK-II that is greater than 200-fold selective over ROCK-I (IC50s = 105 nM and 24 μM, respectively).(In Vitro):Belumosudil (SLx-2119; 40 μM) induces significant down-regulations of Tsp-1 and CTGF mRNA levels in PASMC. The microarray hybridized with aRNA from HMVEC treated with Belumosudil, shows a 5-times higher background than the other arrays.(In Vivo):Belumosudil (KD-025; 100, 200 or 300 mg/kg, i.p.) dose-dependently reduces infarct volume after transient middle cerebral artery occlusion. Belumosudil is at least as efficacious in aged, diabetic or female mice, as in normal adult males.
-
In VitroBelumosudil (SLx-2119; 40 μM) induces significant down-regulations of Tsp-1 and CTGF mRNA levels in PASMC. The microarray hybridized with aRNA from HMVEC treated with Belumosudil, shows a 5-times higher background than the other arrays.
-
In VivoBelumosudil (KD-025; 100, 200 or 300?mg/kg, i.p.) dose-dependently reduces infarct volume after transient middle cerebral artery occlusion. Belumosudil is at least as efficacious in aged, diabetic or female mice, as in normal adult males.
-
SynonymsSLx-2119 | SLx2119 | SLx 2119 | KD 025
-
PathwayOthers
-
TargetOther Targets
-
RecptorROCK2| ROCK2
-
Research AreaCancer
-
Indication——
Chemical Information
-
CAS Number911417-87-3
-
Formula Weight452.51
-
Molecular FormulaC26H24N6O2
-
Purity>98% (HPLC)
-
SolubilityDMSO : ≥ 29 mg/mL; 64.09 mM
-
SMILESC(=O)(COc1cc(ccc1)c1nc2c(c(n1)Nc1cc3cn[nH]c3cc1)cccc2)NC(C)C
-
Chemical Name2-[3-[4-(1H-indazol-5-ylamino)-2-quinazolinyl]phenoxy]-N-(1-methylethyl)-acetamide
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
-
PKG drug G1
PKG drug G1 targets C42 of PKG Iα. PKG drug G1 can couple to vasodilation and blood pressure lowering by a C42 PKG Iα-independent mechanism.
-
ELOVL1-IN-2
ELOVL1-IN-2, a compound known as an inhibitor of the elongation of very long chain fatty acid 1 (ELOVL1) enzyme, exhibits a weak inhibitory effect on ELOVL1 (with an IC50 of 21 μM) and demonstrates moderate potency in a primary cellular assay conducted on HEK293 C26 cells (with an IC50 of 6.7 μM) .
-
UDP-Glucose sodium s...
UDP-Glucose sodium salt is an endogenous nucleotide sugar involved in glycosyltransferase reactions in metabolism. It is an agonist of the P2Y14 receptor (EC50 = 0.35 μM). It can also bind to and activate GPR17 inducing oligodendrocyte differentiation at a maximal concentration of 100 μM.
